Sara Marisa Simonetti on Muck Rack

Sara Marisa Simonetti

As seen in: Nature, BioRxiv, medRxiv, EMJ- European Medical Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sara Marisa

Contact Sara Marisa, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program

|
By Sara Marisa Simonetti, Stephen Pettitt, Paula Proszek, Cristina Viaplana, Lorena Magraner-Pardo, Eduardo García-Galea, Carmen Garcia-Duran, Marcel Romey, Sara Arce-Gallego, Anna Suñol, Flaminia Pedretti, Andrea Herencia-Ropero, Paolo Nuciforo, Mafalda Oliveira, Cristina Saura, Isabel Pimentel, Carsten Denkert, Christopher Lord Verified, Andrew Tutt, Aleix Prat, Rodrigo Dientsmann, Susana Aguilar, Sara Gutiérrez-Enríquez, Joaquin Mateo, Ana Oaknin, Judith Balmaña, Alba Llop-Guevara, Ana Vivancos, Violeta Serra, Heura Domènech, Paula Romero-Lozano, Michaela Smalley, Adela Rodríguez-Hernández, Joanna Domènech-Vivó
| Nature Verified
Abstract PARP inhibitors (PARPi) are effective in tumors with homologous recombination repair (HRR) deficiency (HRD), typically identified by germline/tumor mutations. However, genetic testing may miss intrinsic PARPi sensitivity and resistance. We evaluated strategies to improve detection and longitudinal monitoring of HRD across >500 tumor samples and >20 paired liquid biopsies, integrating genetic, genomic, and functional readouts.
Open in Who Shared Issue with article?

RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer - npj Breast Cancer

|
By Benedetta Pellegrino, Isabel Pimentel, Guillermo Villacampa, Cinzia Solinas, Sara Torres-Esquius, Sara Marisa Simonetti, Chiara Tommasi, Olga Serra, Matilde Corianò, Maria Michiara, Roberta Minari, Beatrice Bortesi, Maria Vittoria Dieci, Matteo Lambertini, Gabriele Zoppoli, Alessio Schirone, Elisabetta Cretella, Laura Cortesi, Enrico Maria Silini, Cristina Saura, Karen Willard-Gallo, Anais Boisson, Antonino Musolino, Violeta Serra, Judith Balmaña, Cristina Cruz, Alba Llop-Guevara, Nicoletta Campanini, Daniela Boggiani, Elena Rapacchi, Chiara Casarini
| Nature Verified
Abstract Advances in breast cancer (BC) therapy are limited by the absence of well-established biomarkers for DNA-damage targeted treatments. We evaluated the predictive and prognostic value of homologous recombination repair (HRR) deficiency (HRD) by RAD51 nuclear foci and stromal tumour-infiltrating lymphocytes (TILs) in early-stage BC patients with suspected germline susceptibility. Among 291 patients, HRD by RAD51 was found in 78.4% of tumours, and 69.8% had low TILs (<30%).
Open in Who Shared Issue with article?

SpinFlowSim: a blood flow simulation framework for histology-informed diffusion MRI microvasculature mapping in cancer

|
By Kinga Bernatowicz, Sara Marisa Simonetti, Anna Voronova, Athanasios Grigoriou
| medRxiv
This study has received support by AstraZeneca. K.B. was a researcher at VHIO (Barcelona, Spain), and is now an employee of AstraZeneca (Barcelona, Spain). AstraZeneca was not involved in the acquisition and analysis of the data, interpretation of the results, or the decision to submit this article for publication in its current form.
Open in Who Shared View Duplicates (2) Issue with article?
See all 6 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified